IPO Week: The Large-Cap Window Reopened, Selectively

The week of April 13 gave the IPO market a real size test. Madison Air, Arxis, Kailera, AEVEX and Alamar all crossed from filing work into priced offerings, raising roughly $4.5 billion before overallotments. That is not a broad reopening. It was a narrow bid for scaled industrials, defense exposure, obesity-drug scarcity and life-science tools, with investors still asking issuers to bring clean terms, recognizable sponsors and enough demand support to matter.

Madison Air set the tone. The indoor air systems company priced 82.7 million Class A shares at $27, the top of its $25 to $27 range, for about $2.23 billion. The company also paired the IPO with a $100 million concurrent Class B private placement to an entity controlled by founder Larry Gies. Size was the story, but so was control: after the transaction, the founder-linked Class B structure left public holders buying into a controlled company rather than a conventional one-share, one-vote industrial listing.

Arxis followed with another sponsor-backed industrial deal that cleared at the high end. The Arcline-backed aerospace, defense, medtech and industrial components supplier priced an upsized 40.5 million-share offering at $28, raising about $1.13 billion. Its book was helped by a plain read on demand: cornerstone investors had indicated interest in as much as $400 million of stock. The catch is governance and leverage. Arcline retains overwhelming voting power after the deal, and the proceeds story is tied partly to balance-sheet repair rather than a clean growth-capital raise.

Biotech Demand Was Specific, Not Broad

Kailera was the week's clearest risk-on print. The obesity drug developer priced 39.1 million shares at $16, the top of range, for $625 million, then jumped more than 60% in its Nasdaq debut. The order book had support from existing holders, including Bain Capital-linked funds and Qatar Investment Authority, which had indicated interest in up to about $225 million of stock. That matters because Kailera is still a clinical-stage wager in a crowded GLP-1 field. Investors were willing to fund size, but the bid was for obesity exposure with late-stage assets, not for biotech beta in general.

Alamar gave the life-science tools side a smaller but cleaner proof point. The precision proteomics company upsized its offering to 11.25 million shares, priced at $17, and raised about $191 million. Its shares opened at $22.60, about 33% above the IPO price, valuing the company near $1.5 billion on debut reporting. Unlike many development-stage health-care issuers, Alamar brought commercial revenue: 2025 revenue was about $74.2 million, up from roughly $25.1 million in 2024. That did not make the valuation easy, but it gave buyers something more tangible than a trial calendar.

Defense Stayed In Favor

AEVEX rounded out the defense theme. The Madison Dearborn-backed unmanned systems and mission-services company priced 16 million Class A shares at $20, above the $19.50 midpoint of its $18 to $21 range, raising $320 million. It was smaller than Madison Air and Arxis, but the same pattern held: a recognizable sponsor, a defense-linked narrative and a large bank group were enough to move the deal from effectiveness to trading. Its structure is less simple than the headline, with LLC units, Class B voting stock and a tax receivable agreement in the prospectus, so the first-day print should not be mistaken for a clean read on ordinary industrial demand.

The Next Tests Are Less Forgiving

The queue behind the priced deals looks more uneven. Yesway moved forward with terms for 13.95 million shares at $20 to $23, a roughly $300 million base deal and as much as about $321 million at the top of range. The convenience-store operator has real scale, with about $2.7 billion of 2025 revenue, but it also brings leverage, private-equity ownership and a consumer-retail story that will need tighter valuation discipline than the week's defense and obesity names.

Nuclea Energy also put numbers around its proposed NYSE listing, with 5.56 million shares indicated at $8 to $10. That is a very different proposition: a pre-revenue nuclear-development issuer with less than $1 million of assets in the latest filing. It may draw thematic attention, but the evidence base is thin enough that it belongs in the speculative lane until the book proves otherwise.

The week mattered because it separated capital access from calendar noise. Large IPOs could still get done, and several traded well immediately after pricing. But the successful deals had obvious hooks: scale, sponsor credibility, defense scarcity, obesity scarcity or measurable commercial traction. The next names will have to show the same kind of specificity. A busier calendar by itself is not the same thing as a healthier market.